Abstract

Argenx SE will report first‑quarter 2026 results on May 7, 2026, Pre‑Market, with consensus pointing to strong year‑over‑year growth in revenue and earnings and investor focus on product sales momentum and the Vyvgart franchise trajectory.

Market Forecast

Based on current projections, Argenx SE is expected to deliver approximately 1.32 billion US dollars in first‑quarter revenue, implying 65.79% year‑over‑year growth; estimated EPS is 5.38, implying 134.87% year‑over‑year growth, and estimated EBIT is 407.52 million US dollars, implying 230.92% year‑over‑year growth. Forecasts do not specify gross margin or net margin for the quarter.

Main business outlook: Product sales remain the core revenue driver and continue to scale across key markets, with the quarterly trajectory supported by the ongoing expansion of the company’s commercial portfolio. The most promising franchise is Vyvgart, which a number of analysts expect to contribute the majority of the company’s 65.79% year‑over‑year revenue increase this quarter, with some previews centering on approximately 1.30 billion US dollars in first‑quarter franchise revenue.

Last Quarter Review

In the prior quarter, Argenx SE reported revenue of 1.32 billion US dollars (+73.69% year‑over‑year), a gross profit margin of 60.22%, net profit attributable to the parent company of 0.53 billion US dollars, a net profit margin of 40.67%, and adjusted EPS of 8.02 (+969.33% year‑over‑year). A key highlight was profitability acceleration, with net profit rising by 54.81% quarter‑on‑quarter and adjusted EPS outperforming consensus by a wide margin. Within the revenue mix, product sales contributed 1.29 billion US dollars (about 97.24% of total), while other operations contributed 36.44 million US dollars.

Current Quarter Outlook

Primary revenue engine: Product sales

Product sales are projected to anchor first‑quarter performance again, with total company revenue estimated at 1.32 billion US dollars and year‑over‑year growth of 65.79%. The scale observed in the fourth quarter—when product sales accounted for roughly 97% of revenue—demonstrates the concentration of commercial momentum in the core franchise, and consensus expects this mix to remain similar near term. From a profitability standpoint, last quarter’s 60.22% gross margin and 40.67% net margin provide a constructive base; while explicit margin guidance is not available for the current quarter, the EBIT forecast of 407.52 million US dollars and EPS estimate of 5.38 imply a still‑solid earnings profile even as operating investments continue.

Operationally, first‑quarter sales will likely be driven by continued patient uptake across approved indications and geographies, as well as deeper penetration into existing prescriber bases. The conversion of new accounts, better treatment persistence, and steady new starts should provide the scaffolding for the projected revenue growth. Inventory and channel dynamics, including ordering cadence around quarter‑ends, can introduce variability, but the consensus revenue forecast suggests underlying demand trends remain favorable.

Most promising franchise: Vyvgart expansion

Analysts highlight the Vyvgart franchise as the principal growth engine, with multiple updates this year reinforcing a supportive near‑term setup. Notably, on February 26, 2026, the company reported positive phase 3 results in ocular myasthenia gravis, meeting the study’s main goal and demonstrating significant improvement in patient‑reported ocular outcomes; this outcome adds to the clinical momentum and may expand eligible patient populations upon potential label progression. On April 17, 2026, a preview noted that Vyvgart remains on a rising adoption trajectory in chronic inflammatory demyelinating polyneuropathy, with survey work suggesting patient share rising to 23% from 18% in coming months; the same preview framed first‑quarter franchise revenue around 1.30 billion US dollars and a path to 5.80 billion US dollars in 2026.

The strategic implication is that near‑term revenue is increasingly diversified across indications within the same franchise, which can support steadier prescription flows and reduce dependence on a single patient segment. For this quarter, the commercial emphasis appears to be on sustaining the pace of new patient additions and maintaining treatment persistence. The Vyvgart momentum also frames expectations for the balance of 2026, where added breadth across generalized myasthenia gravis and CIDP could provide incremental upside to revenue run‑rate if adoption proceeds as analysts anticipate.

Key stock‑price drivers this quarter

The core variable for the equity this quarter is the magnitude and persistence of Vyvgart demand against the elevated revenue base implied by consensus. Execution on patient onboarding and prescriber expansion will shape whether revenue lands at, above, or modestly below the 1.32 billion US dollars projection. Any qualitative commentary on demand cadence into April and early May may be market‑moving given how tightly growth expectations are centered on franchise performance.

Another critical driver is the expense and investment profile as Argenx SE funds commercial expansions and lifecycle development. The EBIT estimate of 407.52 million US dollars signals a balanced approach between growth and profitability; however, investors will parse operating expense trends for signals on forward margin durability. Incremental color on spending to support potential label expansions, as well as timing for new‑indication launches, may influence how the Street recalibrates medium‑term EPS trajectories.

Regulatory and clinical milestones are a further catalyst. The positive ocular myasthenia gravis phase 3 readout in February 2026 adds a tangible near‑term opportunity; any updates on engagement with regulators or next steps toward potential filings could bolster sentiment. Conversely, any delays, unexpected safety signals, or slower‑than‑anticipated commercial conversion in new indications would weigh on the shares. Guidance around full‑year 2026 revenue and EPS, if provided, will be an additional anchor for post‑print price action because it will frame how much of the Vyvgart expansion narrative is already embedded in consensus.

Analyst Opinions

Bullish views dominate recent commentary, with roughly seven bullish or positive‑leaning opinions to one neutral view over the January 1, 2026 to April 30, 2026 period. Wedbush reaffirmed its positive stance on April 17, 2026, highlighting that Vyvgart remains the fastest‑growing therapy in CIDP per its survey work, with patient share expected to rise to 23% from 18%; the preview centered around approximately 1.30 billion US dollars in first‑quarter Vyvgart revenue and a 2026 revenue trajectory of about 5.80 billion US dollars for the franchise, underpinning an Outperform rating and a 1,000 US dollars price target. Citi reiterated a Buy with a 1,152 US dollars price target, emphasizing durable growth potential and continued commercial broadening. Jefferies maintained a Buy with price targets cited at 980 US dollars and later 1,008 US dollars, echoing expectations for sustained demand expansion. RBC Capital kept a Buy rating with price targets cited at 860–890 US dollars, projecting continued uptake and revenue scaling. Evercore ISI reiterated a Buy around a 910 US dollars target based on the forward revenue and earnings profile. UBS maintained Hold at 900 US dollars, but this stance remained the minority view in the period.

The bullish case across these previews centers on three planks for the upcoming print and the near‑term trajectory. First, the demand curve remains constructive, with analysts pointing to continued adoption trends and supportive survey data in CIDP, aligning with the 65.79% year‑over‑year revenue growth implied by consensus for the quarter. Second, earnings power appears resilient even as investments continue, with the Street modeling 407.52 million US dollars of EBIT and EPS of 5.38 for the quarter, suggesting that operating leverage can coexist with disciplined commercial spend. Third, recent clinical progress—such as the positive phase 3 ocular myasthenia gravis readout on February 26, 2026—adds another potential growth leg that can broaden the eligible patient pool and sustain the revenue ramp over 2026.

Taken together, the majority of institutional commentary anticipates that first‑quarter revenue will align with or exceed the 1.32 billion US dollars marker and that management’s color on patient additions, payer dynamics, and indication expansion will be supportive for the rest of the year. Price targets from prominent institutions such as Citi (1,152 US dollars), Jefferies (up to 1,008 US dollars), RBC Capital (up to 890 US dollars), Evercore ISI (910 US dollars), and Wedbush (1,000 US dollars) collectively anchor a bullish skew in expectations. The focus into May 7, 2026 is on whether reported revenue and EPS can meet the high‑growth bar, and whether qualitative guidance reaffirms that the Vyvgart expansion can continue to translate into both top‑line and earnings progression through the balance of 2026.